Bromocriptine mesylate is the mesylate salt of Bromocriptine, an ergoline-derived selective agonist of D2DR and D3DR (D2 and D3 dopamine receptors). Bromocriptine demonstrated a ten-fold higher affinity at D2 over D3 in recombinant dopamine receptors. When Bromocriptine is combined with the D1-selective dopamine receptor agonist SKF38393, normalization of hyperphagia and resultant reductions of body weight and fat, serum glucose, free fatty acid and triglyceride concentrations is reported in agonist-administered ob/ob mice. Bromocriptine mesylate is an inhibitor of NOS1.
1. Perachon, S., et al. 1999. Eur. J. Pharmacol. 366: 293-300. PMID: 10082211
2. Scislowski, P.W., et al. 1999. Int. J. Obes. Relat. Metab. Disord. 23: 425-431. PMID: 10340822
3. Zhang, Y., et al. 1999. Metab. Clin. Exp. 48: 1033-1040. PMID: 10459570
4. Holt, R.I., et al. 2010. Diabetes Obes Metab. 12: 1048-1057. PMID: 20977575
See how others have used Bromocriptine mesylate (CAS 22260-51-1). Click on the entry to view the PubMed entry .
PMID: # 27488872 Huang, J. et al. 2016. Cancer Res Treat.
PMID: # 33062652 Front Vet Sci. 615.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.